FAM
CORT icon

Flaharty Asset Management’s Corcept Therapeutics CORT Stock Holding History

Flaharty Asset Management’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-200
Closed -$5.45K – 179
2023
Q3 		$5.45K Buy
+200
New +$5.79K ﹤0.01% 364

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return

Flaharty Asset Management's CORT Position: Q4 2023 in Review

Flaharty Asset Management sold out of Corcept Therapeutics (CORT) in Q4 2023, closing a stake of 200 shares — an estimated $5.45K sold.

Flaharty Asset Management first reported a position in CORT in Q3 2023 and held it in 1 quarter. The position peaked at $5.45K in Q3 2023. 273 funds tracked by Wall St. Rank hold CORT as of Q4 2023.

  • Flaharty Asset Management reported no remaining Corcept Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Flaharty Asset Management sold 200 Corcept Therapeutics shares in Q4 2023, an estimated $5.45K.
  • Flaharty Asset Management first reported a position in Corcept Therapeutics in Q3 2023 and held it in 1 quarter.
  • Flaharty Asset Management's Corcept Therapeutics position peaked at $5.45K in Q3 2023.
  • 273 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q4 2023.

Based on Flaharty Asset Management's 13F filing for Q4 2023, filed 5 Feb 2024.